Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder
Clinical trial NCT02055638 · COMPLETED
Trial details
- NCT number
- NCT02055638
- Sponsor
- Azevan Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-01
- Primary completion
- 2016-05-01
- Enrollment
- 97
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.